

Bern, April 2024

# SAKK / Novartis Translational Prostate Cancer Research Award

## Award

The Swiss Group for Clinical Cancer Research (SAKK) and Novartis Pharma Schweiz AG are pleased to announce an award for 20 000 CHF aimed at supporting ongoing translational prostate cancer research.

## Eligible Projects

- Projects should be translational in nature. That is, they should be aimed at translating basic research discoveries into the clinic. Possible projects could include, but are not limited to:
  - Development of novel treatments for prostate cancer focused on small molecules, biologics, or radioligand therapies
  - Development of diagnostic modalities for prostate cancer
  - Development of novel prevention strategies for prostate cancer
- Approaches should include preclinical, animal, human tissue, and/or human studies
- Basic research discovery projects are out of scope
- Must be conducted in Switzerland, but can be part of larger collaborative projects. In case of the latter, the submitted project should be a substantial part of such an overarching project and focus on a specific aspect. Only costs that are still occurring can be covered by the award.

## Eligible Applicants

Applicants must have a primary place of work in Switzerland and can include graduate or postgraduate researchers or physician scientists.

## Application Process and Timelines

To be considered for the award, please submit the abstract with no more than 300 words and your CV for this meeting by end of September 2024 to [events@sakk.ch](mailto:events@sakk.ch). Only complete submissions can be considered.

Briefly, the application must:

- Be written in English language
- The abstract of not more than 300 words should include a project title, the rationale, aim of the project, and how this research will be translated into the clinic.

## Jury

The Scientific Committee of the SAKK Translational Urogenital Cancer Network Meeting 2024 will decide on the winning project.

## Criteria for Project Evaluation

Project proposals will only be evaluated if they are deemed to be eligible and feasible according to the project scope defined above. Evaluation will be based on the presentation/abstract and on the following criteria:

- Estimated impact on prostate cancer outcomes
- Reproducibility and translatability of the project
- Novelty of the project



SAKK Competence Center  
Effingerstrasse 33  
CH-3008 Bern  
+41 31 389 91 91  
events@sakk.ch

## Notification and Award Ceremony

The award winner will be announced at the SAKK Translational Urogenital Cancer Network Meeting 2024.

## Contact Details

Questions about this award can be addressed to:  
SAKK Competence Center  
Effingerstrasse 33  
3008 Bern  
Tel +41 31 389 91 91  
E-Mail: [events@sakk.ch](mailto:events@sakk.ch)